Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Interpore Cross International

This article was originally published in The Gray Sheet

Executive Summary

Planned secondary offering of 4 mil. shares will include 500,000 put up by selling shareholders, the firm announces March 15. The Irvine, California company also plans a second-quarter U.S. launch of the TPS (Telescopic Plate Spacer) expandable titanium spacer. The introduction follows the recent receipt of a humanitarian device exemption from FDA for use in replacing one or two spine vertebral bodies removed on account of cancer. Underwriters for the offering include U.S. Bancorp Piper Jaffray and Chase H&Q

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013118

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel